DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Visken (Pindolol) - Summary

 
 



VISKEN SUMMARY

Visken®

Visken® (pindolol), a synthetic beta-adrenergic receptor blocking agent with intrinsic sympathomimetic activity is 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol.

Visken® (pindolol) is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.



See all Visken indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Visken (Pindolol)

Left Ventricular Heart Failure and Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2016.06.23]
This review examines the complex pathophysiology of pulmonary hypertension as it relates to left ventricular heart failure. What are the diagnostic pitfalls, and current therapeutic options?
European Heart Journal

Blood test shows promise in gauging severity of pulmonary arterial hypertension
Source: Respiratory / Asthma News From Medical News Today [2016.06.22]
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial...

The healing powers of music: Mozart and Strauss for treating hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.06.21]
The music of Mozart and Strauss is able to lower blood lipid concentrations and the heart rate.

Aircraft noise may cause hypertension and organ damage
Source: Cardiovascular / Cardiology News From Medical News Today [2016.06.18]
The negative health implications of exposure to aircraft sound are slowly being uncovered. Hypertension and organ damage are the latest to join the list.

Hepatitis C: Once the viral infection has healed, high-risk portal vein hypertension also diminishes
Source: Hypertension News From Medical News Today [2016.06.16]
This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein.

more news >>

Published Studies Related to Visken (Pindolol)

Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. [2011.07]
CONCLUSIONS: Present findings represent further evidence of the acceleration and enhancement of efficacy with pindolol administered together with SSRIs, displaying a quicker and more pronounced decrease of symptoms in patients with nonresistant major depressive disorder. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00931775. (c) Copyright 2011 Physicians Postgraduate Press, Inc.

Pindolol augmentation enhances response outcomes in first depressive episodes. [2009.07]
Effectiveness of Pindolol addition to SSRIs is still a matter of debate.

Glomerular filtration rate after tramadol, parecoxib and pindolol following anaesthesia and analgesia in comparison with morphine in dogs. [2009.01]
OBJECTIVE: To compare the effects of morphine, parecoxib, tramadol and a combination of parecoxib, tramadol and pindolol on nociceptive thresholds in awake animals and their effect on glomerular filtration rate (GFR) in dogs subjected to 30 minutes of anesthesia. ANIMALS: Eight adult mixed breed experimental dogs. STUDY DESIGN: Randomized, controlled trial... CONCLUSION: Tramadol and parecoxib (either alone or in combination) can increase nociceptive thresholds in awake dogs and have minimal effects on renal perfusion in normotensive dogs subjected to anaesthesia.

Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. [2008.02]
Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial...

Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. [2004.06]
Loss of noradrenergic (NE) neurones in the locus ceruleus and compensatory changes in NE activity have been described in Alzheimer's disease (AD), but have never been linked to treatment. The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol...

more studies >>

Clinical Trials Related to Visken (Pindolol)

EScitalopram PIndolol ONset of Action [Terminated]
The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.

Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression [Terminated]
This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder [Completed]
The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) [Completed]
MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.

Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations [Recruiting]
Generic describes a pharmaceutical product that does not have a brand name or trademark. Generic medications should be the equivalent of brand medications. Only their price should be different. The active ingredient of the generic medication has to be within a window of 80 to 125% of the original in the blood. There are reports that this standard is not always followed after the medication has been on the market. Indeed, it was observed that some patients previously stable on original medications relapsed when switched to a generic. Several factors could account for this problem. Such problems have been reported for Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and the original brands will be examined for these three medications. The three original medications used in this study are the Visken, the Seroquel, and the Desyrel. The three generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all available on the Canadian market by prescription.

more trials >>


Page last updated: 2016-06-23

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015